mRNA anti-cancer vaccine - Regen BioPharma
Alternative Names: Modified mRNA anti-cancer vaccine - Regen BioPharmaLatest Information Update: 02 Aug 2022
At a glance
- Originator Regen BioPharma
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 26 Jul 2022 Regen Biopharma files for patent protection with the United States Patent and Trademark Office (USPTO) for mRNA anti-cancer vaccine in USA
- 11 Feb 2022 Early research in Cancer in USA (unspecified route)
- 11 Feb 2022 Regen Biopharma announces intention to submit IND application to US FDA for Cancer (Prevention)